Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events

Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure

(2012) Benjamin W. Van Tassell et al.   PLoS One

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Challenges and Opportunities for Cardiovascular Disease Prevention

(2011) Manuel Franco et al.   AMERICAN JOURNAL OF MEDICINE

Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

(2011) Ahmet Gül et al.   ANNALS OF THE RHEUMATIC DISEASES

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

(2011) N. Schlesinger et al.   ANNALS OF THE RHEUMATIC DISEASES

Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice

(2011) Vinay Bhaskar et al.   ATHEROSCLEROSIS

Canakinumab

(2011) Monique P. Curran   BIODRUGS

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

(2011) C. A. Dinarello   BLOOD

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

(2011) Rieke Alten et al.   BMC MUSCULOSKELETAL DISORDERS

Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial

(2011) P. Kohli et al.   CLINICAL CHEMISTRY

Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care

(2011) Jeffrey R. Curtis et al.   CLINICAL THERAPEUTICS

15 Investigation of IL-1 inhibition in patients presenting with non-ST elevation myocardial infarction acute coronary syndromes (the MRC ILA Heart Study)

(2011) A. C. Morton et al.   HEART

Right ventricular systolic dysfunction in patients with reperfused ST-segment elevation acute myocardial infarction

(2011) Benjamin W. Van Tassell et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice

(2011) Matthew R. Alexander et al.   JOURNAL OF CLINICAL INVESTIGATION

High-Sensitivity C-Reactive Protein Is Within Normal Levels at the Very Onset of First ST-Segment Elevation Acute Myocardial Infarction in 41% of Cases

(2011) Nicole Cristell et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Alterations in the Interleukin-1/Interleukin-1 Receptor Antagonist Balance Modulate Cardiac Remodeling following Myocardial Infarction in the Mouse

(2011) Antonio Abbate et al.   PLoS One

The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse

(2011) E. Mezzaroma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra

(2011) Ignatios Ikonomidis et al.   THROMBOSIS AND HAEMOSTASIS

Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)

(2010) Antonio Abbate et al.   AMERICAN JOURNAL OF CARDIOLOGY

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

(2010) Alexander So et al.   ARTHRITIS AND RHEUMATISM

Heart Disease and Stroke Statistics—2011 Update

(2010) Véronique L. Roger et al.   CIRCULATION

Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes

(2010) Luis C.L. Correia et al.   CLINICA CHIMICA ACTA

XOMA 052, an Anti-IL-1β Monoclonal Antibody, Improves Glucose Control and β-Cell Function in the Diet-Induced Obesity Mouse Model

(2010) Alexander M. Owyang et al.   ENDOCRINOLOGY

Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

(2010) Antonio Abbate et al.   EUROPEAN JOURNAL OF HEART FAILURE

Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

(2010) Marina K. Roell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Pharmacologic Inhibition of Myeloid Differentiation Factor 88 (MyD88) Prevents Left Ventricular Dilation and Hypertrophy After Experimental Acute Myocardial Infarction in the Mouse

(2010) Benjamin W Van Tassell et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Interleukin-1 Trap Attenuates Cardiac Remodeling After Experimental Acute Myocardial Infarction in Mice

(2010) Benjamin W Van Tassell et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Blocking interleukin-1β in acute and chronic autoinflammatory diseases

(2010) C. A. Dinarello   JOURNAL OF INTERNAL MEDICINE

CARDIOVASCULAR EFFECTS OF TUMOUR NECROSIS FACTOR ALPHA ANTAGONISM IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION

(2010) Gareth J. Padfield et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals

(2010) Peter Duewell et al.   NATURE

Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation

(2010) Kristiina Rajamäki et al.   PLoS One

Rilonacept-CAPS and Beyond

(2009) Neil Stahl et al.   Annals of the New York Academy of Sciences

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

(2009) R Terkeltaub et al.   ANNALS OF THE RHEUMATIC DISEASES

Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis

(2009) I Ikonomidis et al.   HEART

Inflammasomes: too big to miss

(2009) Andrea Stutz et al.   JOURNAL OF CLINICAL INVESTIGATION

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)

(2009) PAUL M. RIDKER   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2009)   LANCET

Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach

(2009) James H. O'Keefe et al.   MAYO CLINIC PROCEEDINGS

Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding

(2009) Janet Chamberlain et al.   PLoS One

Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis

(2008) Ignatios Ikonomidis et al.   CIRCULATION

Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction

(2008) Antonio Abbate et al.   CIRCULATION

Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction

(2008) Raghava S. Velagaleti et al.   CIRCULATION

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

(2008) Robert S Wallis   LANCET INFECTIOUS DISEASES

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)

(2008) David C Crossman et al.   Trials

Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation

(2007) A Abbate et al.   HEART

Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease—A randomized placebo-controlled study

(2006) Juliano Lara Fernandes et al.   ATHEROSCLEROSIS